Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655402 | 0.80 | ALDH1A1 (0.43) | CYP2C19CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6526804 | 0.74 | MEN1 (0.36) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5657589 | 0.73 | POLB (0.39) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5657882 | 0.73 | POLB (0.39) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5657910 | 0.71 | ALOX5AP (0.32) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5656048 | 0.71 | CYP1A2 (0.32) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22534195 | 0.71 | CYP1A2 (0.30) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3458773 | 0.69 | ALDH1A1 (0.30) | — | |
| SCHEMBL21558721 | 0.68 | KCNH2 (0.34) | — | |
| SCHEMBL15996487 | 0.68 | ADORA2A (0.33) | CYP2C19CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | CYP2C19 70/4885CYP1A2 6/4885CYP3A4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.